Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A SAFETY AND EFFICACY STUDY OF ADDING LOW DOSE PEGYLATED IFN-ALPHA 2B TO STANDARD DOSE DASATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA

Next Previous
X
Search
Trial Profile

A SAFETY AND EFFICACY STUDY OF ADDING LOW DOSE PEGYLATED IFN-ALPHA 2B TO STANDARD DOSE DASATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasatinib (Primary) ; Peginterferon alfa-2b (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NordCML007

    • Most Recent Events

    • 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 06 Dec 2016 Results of substudy assessing immune effects of dasatinib and interferon combination treatment presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 18 Jul 2016 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top